Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | DPYD | Q12882 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789315 | 1.00 | NPC1 (0.50) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL27915130 | 0.83 | DPYD (0.39) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL14473118 | 0.79 | ADORA2A (0.54) | KMT2AKDM4EALDH1A1MAPTADORA2A | |
| SCHEMBL9585370 | 0.76 | NPC1 (0.48) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL9585367 | 0.76 | NPC1 (0.48) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL7288931 | 0.69 | ADORA2A (0.76) | KDM4EALDH1A1ADORA2ACYP1A2CYP2D6 | |
| SCHEMBL7402395 | 0.69 | ADORA2A (0.76) | KDM4EALDH1A1ADORA2ACYP1A2CYP2D6 | |
| SCHEMBL561427 | 0.69 | ADORA2B (0.55) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL561426 | 0.69 | ADORA2B (0.55) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL8810819 | 0.68 | NOD1 (0.39) | RAB9AKMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | claimed |
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | claimed |
| WO-2010065959-A1 | METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY | NORTHEASTERN UNIVERSITY (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2111231-A2 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NorthEastern University (US) | 2009-10-28 | — | — | EP | claimed |
| EP-1765352-A4 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | UNIV CALIFORNIA (US) | 2009-07-08 | — | — | EP | claimed |
| WO-2008147482-A2 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2008-12-04 | — | — | WO | claimed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | claimed |
| CN-101060841-A | Antagonizing an adenosine A2A receptor to amelioriate one or more components of addictive behavior | UNIV CALIFORNIA (US) | 2007-10-24 | — | — | CN | claimed |
| EP-1765352-A2 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | The Regents of the University of California (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060128708-A1 | Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-06-15 | — | — | US | claimed |
| WO-2006009698-A2 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | WO | claimed |
| US-20190083497-A1 | MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY | UNIV CORNELL (US) | 2019-03-21 | — | — | US | disclosed |
| EP-2274007-B1 | MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY | UNIV CORNELL (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-102014959-B | Modulation of blood brain barrier permeability | CORNELL UNIVERSITY (US) | 2016-01-20 | — | — | CN | disclosed |
| US-8883500-B2 | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy | NORTHEASTERN UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | disclosed |
| CN-101060841-A | Antagonizing an adenosine A2A receptor to amelioriate one or more components of addictive behavior | UNIV CALIFORNIA (US) | 2007-10-24 | — | — | CN | disclosed |
| EP-1765352-A2 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | The Regents of the University of California (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060128708-A1 | Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-06-15 | — | — | US | disclosed |
| WO-2006009698-A2 | ANTAGONIZING AN ADENOSINE A2A RECEPTOR TO AMELIORIATE ONE OR MORE COMPONENTS OF ADDICTIVE BEHAVIOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | ADORA2A, ADORA2B, ADORA3 | NPC1 4003/4885RAB9A 1925/4885KMT2A 3229/4885 |
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | HIF1AN, HIF1A, EGLN3 | NPC1 2139/4885RAB9A 3009/4885KMT2A 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.